✦ LIBER ✦

Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors

✍ Scribed by Shreyaskumar R. Patel

Book ID: 107546225
Publisher: Current Science Inc.
Year: 2003
Tongue: English
Weight: 58 KB
Volume: 5
Category: Article
ISSN: 1523-3790
DOI: 10.1007/s11912-003-0070-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of neoadjuvant/adjuvant i

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

✍ Burton L. Eisenberg; Jonathan Harris; Charles D. Blanke; George D. Demetri; Mich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

Sole brachytherapy of the tumor bed afte

Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: Five-year results of a phase I–II study and initial findings of a randomized phase III trial

✍ Csaba Polgár; Zoltán Sulyok; János Fodor; Zsolt Orosz; Tibor Major; Zoltán Takác 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 1 views

Rituximab for rheumatoid arthritis refra

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

✍ Stanley B. Cohen; Paul Emery; Maria W. Greenwald; Maxime Dougados; Richard A. Fu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 3 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views